Curetis, Bei­jing Clear Biotech ex­pand strate­gic col­lab­o­ra­tion

BioSpectrum (Asia) - - COMPANY NEWS -

Curetis, a de­vel­oper of next-level molec­u­lar di­ag­nos­tic solutions, has an­nounced that it has sig­nif­i­cantly ex­panded its strate­gic col­lab­o­ra­tion with Bei­jing Clear Biotech (BCB) for the ex­clu­sive dis­tri­bu­tion of the Unyvero A50 Plat­form and Unyvero A50 Ap­pli­ca­tion Car­tridges in Greater China. The par­ties have amended their ex­clu­sive in­ter­na­tional dis­tri­bu­tion agree­ment, orig­i­nally signed in Septem­ber 2015, to ex­pand the term of the Agree­ment from five to eight years from the first reg­u­la­tory ap­proval in China. The amended agree­ment has also ex­panded the to­tal com­mit­ment of BCB for cu­mu­la­tive min­i­mum pur­chases to more than 360 Unyvero A50 Sys­tems from 260 Sys­tems pre­vi­ously and over 1.5 mil­lion Unyvero Ap­pli­ca­tion A50 Car­tridges from about 550,000 Car­tridges pre­vi­ously for the du­ra­tion of the Agree­ment. This min­i­mum com­mit­ment would in­di­cate po­ten­tial rev­enues to Curetis of over EUR 30 mil­lion an­nu­ally in years six to eight of com­mer­cial­iza­tion in China in ad­di­tion to po­ten­tial cu­mu­la­tive rev­enues of more than EUR 60 mil­lion for years one to five of com­mer­cial­iza­tion in China as agreed upon pre­vi­ously.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.